SK Biopharmaceuticals
SK Biopharmaceuticals, a leading player in the biopharmaceutical industry, is headquartered in South Korea (KR) and operates extensively across Asia, Europe, and North America. Founded in 2011, the company has rapidly established itself as a pioneer in developing innovative therapies for neurological disorders, particularly epilepsy. With a strong focus on research and development, SK Biopharmaceuticals has achieved significant milestones, including the successful launch of its flagship product, cenobamate, which offers unique mechanisms of action for seizure control. The company is recognised for its commitment to advancing healthcare solutions, positioning itself as a key contributor to the global biopharmaceutical landscape. Through its dedication to innovation and patient-centric approaches, SK Biopharmaceuticals continues to enhance its market presence and reputation.
DitchCarbon Score
How does SK Biopharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SK Biopharmaceuticals's score of 34 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
SK Biopharmaceuticals's reported carbon emissions
In 2023, SK Biopharmaceuticals reported total carbon emissions of approximately 12,882,000 kg CO2e, comprising 433,000 kg CO2e from Scope 1, 1,046,000 kg CO2e from Scope 2, and 11,882,000 kg CO2e from Scope 3 emissions. This represents a slight increase in emissions compared to 2022, where total emissions were about 7,147,000 kg CO2e, with Scope 1 at 425,000 kg CO2e, Scope 2 at 936,000 kg CO2e, and Scope 3 at 6,547,000 kg CO2e. The company has disclosed emissions data for all three scopes, indicating a commitment to transparency in its climate impact. However, there are currently no specific reduction targets or initiatives outlined in their sustainability reports. This lack of defined targets suggests that while SK Biopharmaceuticals is aware of its emissions profile, it may need to establish clearer strategies for reducing its carbon footprint in the future. Overall, SK Biopharmaceuticals' emissions data highlights the significant role of Scope 3 emissions in its overall carbon footprint, which is common in the biopharmaceutical industry, where upstream and downstream activities often contribute the majority of emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 328,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 841,000 | 000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 0,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SK Biopharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
